These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

266 related articles for article (PubMed ID: 21418221)

  • 41. Neurofilaments as Biomarkers for Amyotrophic Lateral Sclerosis: A Systematic Review and Meta-Analysis.
    Xu Z; Henderson RD; David M; McCombe PA
    PLoS One; 2016; 11(10):e0164625. PubMed ID: 27732645
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Soluble beta-amyloid precursor protein is related to disease progression in amyotrophic lateral sclerosis.
    Steinacker P; Fang L; Kuhle J; Petzold A; Tumani H; Ludolph AC; Otto M; Brettschneider J
    PLoS One; 2011; 6(8):e23600. PubMed ID: 21858182
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Diagnostic and prognostic value of CSF neurofilaments in a cohort of patients with motor neuron disease: A cross-sectional study.
    Gagliardi D; Faravelli I; Meneri M; Saccomanno D; Govoni A; Magri F; Ricci G; Siciliano G; Pietro Comi G; Corti S
    J Cell Mol Med; 2021 Apr; 25(8):3765-3771. PubMed ID: 33609080
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Combined use of CSF NfL and CSF TDP-43 improves diagnostic performance in ALS.
    Kasai T; Kojima Y; Ohmichi T; Tatebe H; Tsuji Y; Noto YI; Kitani-Morii F; Shinomoto M; Allsop D; Mizuno T; Tokuda T
    Ann Clin Transl Neurol; 2019 Dec; 6(12):2489-2502. PubMed ID: 31742901
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Comparative diagnosis interest of NfL and pNfH in CSF and plasma in a context of FTD-ALS spectrum.
    Escal J; Fourier A; Formaglio M; Zimmer L; Bernard E; Mollion H; Bost M; Herrmann M; Ollagnon-Roman E; Quadrio I; Dorey JM
    J Neurol; 2022 Mar; 269(3):1522-1529. PubMed ID: 34313819
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Elevated cerebrospinal fluid neurofilament light levels in patients with amyotrophic lateral sclerosis: a possible marker of disease severity and progression.
    Tortelli R; Ruggieri M; Cortese R; D'Errico E; Capozzo R; Leo A; Mastrapasqua M; Zoccolella S; Leante R; Livrea P; Logroscino G; Simone IL
    Eur J Neurol; 2012 Dec; 19(12):1561-7. PubMed ID: 22680408
    [TBL] [Abstract][Full Text] [Related]  

  • 47. CSF glial markers correlate with survival in amyotrophic lateral sclerosis.
    Süssmuth SD; Sperfeld AD; Hinz A; Brettschneider J; Endruhn S; Ludolph AC; Tumani H
    Neurology; 2010 Mar; 74(12):982-7. PubMed ID: 20308682
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Cerebrospinal fluid macrophage biomarkers in amyotrophic lateral sclerosis.
    Thompson AG; Gray E; Thézénas ML; Charles PD; Evetts S; Hu MT; Talbot K; Fischer R; Kessler BM; Turner MR
    Ann Neurol; 2018 Feb; 83(2):258-268. PubMed ID: 29331073
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Neurofilament levels in patients with neurological diseases: A comparison of neurofilament light and heavy chain levels.
    Kušnierová P; Zeman D; Hradílek P; Čábal M; Zapletalová O
    J Clin Lab Anal; 2019 Sep; 33(7):e22948. PubMed ID: 31199010
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Validation of serum neurofilaments as prognostic and potential pharmacodynamic biomarkers for ALS.
    Benatar M; Zhang L; Wang L; Granit V; Statland J; Barohn R; Swenson A; Ravits J; Jackson C; Burns TM; Trivedi J; Pioro EP; Caress J; Katz J; McCauley JL; Rademakers R; Malaspina A; Ostrow LW; Wuu J;
    Neurology; 2020 Jul; 95(1):e59-e69. PubMed ID: 32385188
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Elevated CSF TDP-43 levels in amyotrophic lateral sclerosis: specificity, sensitivity, and a possible prognostic value.
    Noto Y; Shibuya K; Sato Y; Kanai K; Misawa S; Sawai S; Mori M; Uchiyama T; Isose S; Nasu S; Sekiguchi Y; Fujimaki Y; Kasai T; Tokuda T; Nakagawa M; Kuwabara S
    Amyotroph Lateral Scler; 2011 Mar; 12(2):140-3. PubMed ID: 21126161
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Inflammatory markers in cerebrospinal fluid: independent prognostic biomarkers in amyotrophic lateral sclerosis?
    Gille B; De Schaepdryver M; Dedeene L; Goossens J; Claeys KG; Van Den Bosch L; Tournoy J; Van Damme P; Poesen K
    J Neurol Neurosurg Psychiatry; 2019 Dec; 90(12):1338-1346. PubMed ID: 31175169
    [TBL] [Abstract][Full Text] [Related]  

  • 53. YKL40 in sporadic amyotrophic lateral sclerosis: cerebrospinal fluid levels as a prognosis marker of disease progression.
    Andrés-Benito P; Domínguez R; Colomina MJ; Llorens F; Povedano M; Ferrer I
    Aging (Albany NY); 2018 Sep; 10(9):2367-2382. PubMed ID: 30215603
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Phosphorylated tau as a candidate biomarker for amyotrophic lateral sclerosis.
    Grossman M; Elman L; McCluskey L; McMillan CT; Boller A; Powers J; Rascovsky K; Hu W; Shaw L; Irwin DJ; Lee VM; Trojanowski JQ
    JAMA Neurol; 2014 Apr; 71(4):442-8. PubMed ID: 24492862
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Amyotrophic lateral sclerosis: Correlations between fluid biomarkers of NfL, TDP-43, and tau, and clinical characteristics.
    Kojima Y; Kasai T; Noto YI; Ohmichi T; Tatebe H; Kitaoji T; Tsuji Y; Kitani-Morii F; Shinomoto M; Allsop D; Teramukai S; Mizuno T; Tokuda T
    PLoS One; 2021; 16(11):e0260323. PubMed ID: 34843548
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Tau protein as a diagnostic and prognostic biomarker in amyotrophic lateral sclerosis.
    Agnello L; Colletti T; Lo Sasso B; Vidali M; Spataro R; Gambino CM; Giglio RV; Piccoli T; Bivona G; La Bella V; Ciaccio M
    Eur J Neurol; 2021 Jun; 28(6):1868-1875. PubMed ID: 33638255
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Neurodegenerative biomarkers outperform neuroinflammatory biomarkers in amyotrophic lateral sclerosis.
    Kläppe U; Sennfält S; Lovik A; Finn A; Bofaisal U; Zetterberg H; Blennow K; Piehl F; Kmezic I; Press R; Samuelsson K; Månberg A; Fang F; Ingre C
    Amyotroph Lateral Scler Frontotemporal Degener; 2024 Feb; 25(1-2):150-161. PubMed ID: 37789557
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Neurofilament changes in serum and cerebrospinal fluid after acute ischemic stroke.
    Pujol-Calderón F; Portelius E; Zetterberg H; Blennow K; Rosengren LE; Höglund K
    Neurosci Lett; 2019 Apr; 698():58-63. PubMed ID: 30599262
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Combination of serum and CSF neurofilament-light and neuroinflammatory biomarkers to evaluate ALS.
    Brodovitch A; Boucraut J; Delmont E; Parlanti A; Grapperon AM; Attarian S; Verschueren A
    Sci Rep; 2021 Jan; 11(1):703. PubMed ID: 33436881
    [TBL] [Abstract][Full Text] [Related]  

  • 60. CSF neurofilament protein analysis in the differential diagnosis of ALS.
    Reijn TS; Abdo WF; Schelhaas HJ; Verbeek MM
    J Neurol; 2009 Apr; 256(4):615-9. PubMed ID: 19296046
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.